VIAMET PHARMACEUTICALS
Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allows them to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors.
VIAMET PHARMACEUTICALS
Industry:
Biotechnology Medical Device Pharmaceutical
Founded:
2005-01-01
Address:
Morrisville, North Carolina, United States
Country:
United States
Website Url:
http://www.viamet.com
Total Employee:
11+
Status:
Closed
Contact:
(919) 467-8539
Email Addresses:
[email protected]
Total Funding:
120.15 M USD
Technology used in webpage:
Domain Not Resolving
Current Advisors List
Current Employees Featured
Founder
Investors List
U.S. Department of Defense
U.S. Department of Defense investment in Grant - Viamet Pharmaceuticals
Intersouth Partners
Intersouth Partners investment in Series D - Viamet Pharmaceuticals
Novartis Venture Fund
Novartis Venture Fund investment in Series D - Viamet Pharmaceuticals
Astellas Venture Management
Astellas Venture Management investment in Series D - Viamet Pharmaceuticals
Lilly Ventures
Lilly Ventures investment in Series D - Viamet Pharmaceuticals
Hatteras Venture Partners
Hatteras Venture Partners investment in Series D - Viamet Pharmaceuticals
Lurie Investment Fund
Lurie Investment Fund investment in Series B - Viamet Pharmaceuticals
Lilly Ventures
Lilly Ventures investment in Series B - Viamet Pharmaceuticals
Novartis Venture Fund
Novartis Venture Fund investment in Series B - Viamet Pharmaceuticals
Hatteras Venture Partners
Hatteras Venture Partners investment in Series B - Viamet Pharmaceuticals
Official Site Inspections
http://www.viamet.com
- Host name: a2aa9ff50de748dbe.awsglobalaccelerator.com
- IP address: 15.197.148.33
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Viamet Pharmaceuticals"
Viamet Pharmaceuticals - Crunchbase Company Profile …
Viamet discovers and develops small molecule inhibitors via an enzyme binding approach for the treatment of various diseases. View contacts for Viamet …See details»
Viamet - Malin PLC
Viamet represents a financial interest for Malin in VIVJOAâ„¢, an FDA-approved medication for the treatment of recurrent vulvovaginal candidiasis (RVVC), an unmet need in women’s health, …See details»
Viamet Pharmaceuticals Holdings - PitchBook
Mar 10, 2017 · Information on valuation, funding, acquisitions, investors, and executives for Viamet Pharmaceuticals Holdings. Use the PitchBook Platform …See details»
Viamet - VentureRadar
Viamet is a biopharmaceutical company focused on the discovery, development and commercialization of novel antifungal agents based on its proprietary metalloenzyme …See details»
Viamet Pharmaceuticals - LinkedIn
Viamet Pharmaceuticals | 809 followers on LinkedIn. Viamet discovers and develops breakthrough therapies based on our leadership in metalloenzyme chemistry and biology. Our …See details»
Viamet Pharmaceuticals - Malin PLC
May 8, 2015 · Founded in 2005, Viamet is a North Carolina (U.S.) based drug discovery company focused on the development and commercialisation of novel small molecule drugs that target …See details»
Viamet Pharmaceuticals - Products, Competitors, Financials, …
Viamet Pharmaceuticals discovers and develops breakthrough therapies based on specialization in metalloenzyme chemistry and biology. The company's clinical portfolio includes novel …See details»
Viamet Pharmaceuticals Holdings, LLC - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Viamet Pharmaceuticals Holdings, LLC of Foxboro, MA. Get the latest business insights from Dun & …See details»
Viamet Pharmaceuticals - Funding, Financials, Valuation & Investors
Viamet discovers and develops small molecule inhibitors via an enzyme binding approach for the treatment of various diseases.See details»
Viamet Pharmaceuticals - Contacts, Employees, Board Members, …
Viamet discovers and develops small molecule inhibitors via an enzyme binding approach for the treatment of various diseases.See details»
NovaQuest Capital Management to Acquire Viamet ... - Malin PLC
Upon closing of the acquisition, Viamet Pharmaceuticals will be a portfolio company of NovaQuest Capital, which will focus on further development of VT-1161 and related assets.See details»
Viamet | VentureRadar
Viamet is a biopharmaceutical company focused on the discovery, development and commercialization of novel antifungal agents based on its proprietary metalloenzyme …See details»
Viamet Pharmaceuticals CEO, Founder, Key Executive Team, Board …
Explore {Viamet Pharmaceuticals's key management people. Discover current leadership team members including founders, CEO, other executives and board directors.See details»
Novaquest Capital Management acquires Viamet Pharmaceuticals
Jan 3, 2018 · Acquiring Organization: Novaquest Capital Management NovaQuest Capital Management provides a range of customized, structured finance investments to meet the …See details»
Viamet Pharmaceuticals Secures $18 Million Financing
Jul 7, 2009 · RESEARCH TRIANGLE PARK, N.C. -- Viamet Pharmaceuticals, Inc. announced today that it has secured $18 million in a Series B financing to accelerate the development of …See details»
NovaQuest Capital Management to Acquire Viamet …
Jan 3, 2018 · About Viamet Pharmaceuticals (www.viamet.com) Viamet Pharmaceuticals discovers and develops breakthrough therapies based on our leadership in metalloenzyme …See details»
Viamet drops IPO, spins out cancer drug as ex-Elan chief funds …
Oct 22, 2014 · Confronted by an increasingly tough group of biotech investors, Research Triangle Park, NC-based Viamet Pharmaceuticals has scrapped plans for an IPO, instead opting to …See details»
Mycovia announces partnerships for VT-1161 - FT.com
Mycovia acquired Viamet's lead anti-fungal drug, VT-1161 in 2018 but Viamet retains a significant economic interest by means of its share of potential milestone payments and sales royalties...See details»
A Randomized Phase 2 Study of VT-1161 for the Treatment of
Oct 5, 2021 · VT-1161 (oteseconazole) is an oral agent with increased selectivity for fungal CYP51. In this phase 2 clinical study, we evaluated the efficacy and safety of VT-1161 vs …See details»
NovaQuest Capital Management to Acquire Viamet …
Upon closing of the acquisition, Viamet Pharmaceuticals will be a portfolio company of NovaQuest Capital, which will focus on further development of VT-1161 and related assets.See details»